1. Market Research
  2. > Pharmaceutical Market Trends
IV and Oral Iron Drugs Market - Global Outlook and Forecast 2019-2024

IV and Oral Iron Drugs Market - Global Outlook and Forecast 2019-2024

  • June 2019
  • 241 pages
  • ID: 5779105
  • Format: PDF
  • By Arizton

Summary

Table of Contents

Search Inside

The IV and oral iron drugs market is expected to reach around $7.69 million by 2024, growing at a CAGR of about 11% during 2018–2024.

The IV and oral iron drugs market is expected to be driven by multiple factors such as expanding the pool of target population with iron deficiency, the high demand for non-dextran IV iron therapeutics, the increasing demand for iron drugs among dialysis and non-dialysis patients, and the commercial availability of branded iron therapeutics.

The growing prevalence of iron deficiency is driving vendors, government organizations, and healthcare professionals to increase awareness about iron replacement therapies. This is expected to impact the IV and oral iron drugs market significantly. Several types of research and clinical studies have confirmed that early diagnosis and prompt treatment improves the quality of life and physical condition of IDA patients and alleviates fatigue and cognitive deficits. Further, the expected commericlization of branded IV drugs such as Feraccru, Monofer, and Injectafer in newer markets will contribute to the growth of the global IV and oral iron drugs market.

Currently, the IV and oral iron drugs market is scaling new heights due to the increase in strategic collaborations and licensing opportunities. These strategic partnerships and in-licensing/out-licensing opportunities will allow key players to gain competitive advantage and increase geographical reach. Further, they will also reduce R&D expenses and offer scope for easy market access among geographies. Originator companies are partnering with large and medium-sized, regional and local, and biotechnology companies to increase the penetration of IV and oral iron drugs worldwide. They are also opting for strategic alliances to receive additional funds for the continued commercialization of drugs among geographies.

The research report on the IV and oral iron drugs market covers market sizing and forecast, market share, industry trends, growth drivers, and vendor analysis. The study includes insights on segmentation by Route of Administration (oral and intravenous), applications (nephrology, OBGYN, surgeries, gastroenterology, oncology, and heart failure), and geography (North America, Europe, APAC, and ROW).

The study considers the present scenario of the IV and oral iron drugs market and its market dynamics for the period 2019'2024. The report covers a detailed overview of several market growth enablers, restraints, and trends. It covers both the demand and supply aspect of the market. It profiles and analyzes leading and prominent companies operating in the IV and oral iron drugs market.

IV and Oral Iron Drugs Market: Segmentation

This market research report includes a detailed segmentation of the market by Route of Administration (ROA), application, and geography. The IV and oral iron drugs market by ROA can be segmented into oral iron drugs and intravenous (IV) iron drugs. The oral iron drugs segment captured more than half of the market in 2018. Oral iron drugs are generally used as the first line of treatment to overcome iron deficiency among children, adults, especially pregnant women. The IV iron drugs market is growing at a faster rate due to expected launches of several branded IV iron drugs in the medicine market. One of the major factors for the significant growth for IV iron drugs is the increased uptake of branded IV drugs in the US and European markets. Hence, the rising global medicine and healthcare expenditure and the accurate and convenient access to IV iron dosages are expected to drive IV and oral iron drugs market during the forecast period.
The IV and oral iron drugs market by application is segmented into nephrology, OBGYN, surgeries, gastroenterology, oncology, and heart failure. In 2018, the nephrology segment accounted for a share of more than half of the IV and oral iron drugs market. The availability of approved prescription iron drugs and the increased demand for IV iron drugs, especially in developed economies for treating ID/IDA in CKD patients are further driving market growth. Over the past few years, the IV and oral iron drugs market has witnessed new IV iron formulations such as iron sucrose. It is replacing high molecular weight iron dextran, especially in dialysis patients. The OBGYN segment constituted around one-third share of the IV and oral iron drugs market in 2018. Also, the IV and oral iron drugs market for gastroenterology is growing at a significant rate and is likely to increase at a similar pace during the forecast period due to the increased need for iron drugs among patients with GI diseases such as IBD and celiac disease.

Market Segmentation by ROA
• Oral Iron Drug
• IVIron Drugs
Market Segmentation by Application
• Nephrology
• OBGYN
• Surgeries
• Gastroenterology
• Oncology
• Heart failure (HF)

IV and Oral Iron Drugs Market: Geography

The IV and oral iron drugs market by geography can be segmented into North America, Europe, APAC, and ROW. In 2018, North America dominated the market and is expected to grow at a CAGR of around 13% during the forecast period. The strong presence of major vendors and a large proportion of the population with ID, coupled with better treatment access to ID and IDA, especially branded drugs, is the primary factor for high market shares. Europe is the second largest market for IV & oral iron drugs. Germany, the UK, France, Italy, and Spain are the major revenue contributors in the region. High disease awareness, high uptake of branded iron therapeutics, and accelerated healthcare spending are the primary factors responsible for market growth. APAC is the third largest market for iron therapeutics. It is expected to grow at a steady rate in the coming years due to growing awareness about the application of iron drugs for chronic disorders. The IV and oral iron drugs market in ROW is growing at a moderate rate. Most end-users prefer generic and OTC oral iron drugs over branded ones in these regions. Brazil, Egypt, Iran, Israel, Mexico, South Arabia, and South Africa are expected to emerge as major markets for IV and oral iron drugs in ROW.

Market Segmentation by Geography
• North America
o US
o Canada
• Europe
o Germany
o UK
• APAC
o Japan
o China
• ROW
o Brazil

Key Vendor Analysis
The IV and oral iron drugs market is characterized by the presence of a few global and many regional and local players. The vendors are offering branded oral and IV iron drugs, which are generating significant revenues, especially Europe and the US. Therefore, the IV and oral iron drugs market has huge growth potential for branded drugs in these markets. The demand for branded drugs is low in many developing and low-income countries due to the availability of low-cost generic drugs, especially oral iron drugs.

Leading Vendors
• Daiichi Sankyo Company
• Vifor Pharma

Other Prominent Vendors
• Akebia Therapeutics
o Business Overview
o Major Product Offerings
• Allergan
• AMAG Pharmaceuticals
• AOP Orphan Pharmaceuticals
• Pharmacosmos
• Sanofi
• Shield Therapeutics

Other Vendors
• AZAD Pharma
• Cirondrugs
• MEDICE
• Pfizer
• Salveo Lifecare
• Sunny Pharmaceutical

Key Market Insights
The analysis of the IV and oral iron drugs market provides market sizing and growth opportunities for the forecast period 2019–2024.
• Offers market sizing and growth prospects of the IV and oral iron drugs market for the forecast period 2019–2024
• Provides comprehensive insights on the latest industry trends, market forecast, and growth drivers in the IV and oral iron drugs market
• Includes a detailed analysis of market growth drivers, challenges, and investment opportunities
• Delivers a complete overview of market segments and the regional outlook of the IV and oral iron drugs market
• Offers an exhaustive summary of the vendor landscape, competitive analysis, and key market strategies to gain a competitive advantage in the IV and oral iron drugs market

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
10% Off

($4000)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Veronica helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Deep Vein Thrombosis (DVT) Global Clinical Trials Review, H1, 2019

Deep Vein Thrombosis (DVT) Global Clinical Trials Review, H1, 2019

  • $ 2500
  • April 2019

Deep Vein Thrombosis (DVT) Global Clinical Trials Review, H1, 2019SummaryGlobalData’s clinical trial report, “Deep Vein Thrombosis (DVT) Global Clinical Trials Review, H1, 2019" provides an overview ...

Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2019

Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2019

  • $ 2500
  • May 2019

Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2019SummaryGlobalData’s clinical trial report, “Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Global ...

Diabetic Retinopathy Global Clinical Trials Review, H1, 2019

Diabetic Retinopathy Global Clinical Trials Review, H1, 2019

  • $ 2500
  • May 2019

Diabetic Retinopathy Global Clinical Trials Review, H1, 2019SummaryGlobalData’s clinical trial report, “Diabetic Retinopathy Global Clinical Trials Review, H1, 2019" provides an overview of Diabetic ...


ref:plp2019

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on